ArticleChinese journal of integrative medicine2026
Sanren Decoction Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Protecting Mitochondrial Function.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unraveling the ameliorative effects of Ling-Gui-Zhu-Gan decoction on MASLD: an integrative gut microbiota and lipidomic study.Frontiers in microbiology · 2026Article
- Anticancer effects of Commiphora myrrha extract on colorectal cancer through regulation of metastasis, cell cycle progression, and apoptosis in vitro and in vivo.Medical oncology (Northwood, London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effects of Sanren Decoction (SRD) on metabolic dysfunction-associated steatotic liver disease (MASLD) induced by high-fat diet (HFD) based on the protective effect of hepatocyte mitochondrial function.
methodsThirty-six male C57BL/6 mice were randomly assigned to 4 groups using stratified sampling based on body weight, including control, HFD, low-dose (10.09 g/kg) and high-dose (20.18 g/kg) SRD groups (n=9). MASLD model was induced in mice via a 16-week HFD. Liver histopathology was assessed using haematoxylin and eosin (HE) and Oil red O staining, while hepatic triglycerides (TG), serum alanine aminotransferase (ALT), fasting blood glucose (FBG), and fasting serum insulin levels were measured using commercial kits. Hepaticmetabolic profiling were analyzed and differential metabolite analysis was performed using partial least squares discriminant analysis and Kyoto Encyclopedia of Genes and Genomes pathways. Mitochondrial microstructure was assessed by electron microscopy. The protein expressions of respiratory chain complexes I-V were determined by Western blot analysis, while the activities of complexes I and II were measured using commercial kits.
resultsIn the HFD-induced MASLD model, 4-week SRD treatment improved hepatic steatosis, inflammation, and hepatocyte ballooning (P<0.05). High-dose SRD treatment significantly reduced hepatic TG, ALT levels, and improved insulin sensitivity (both P<0.05). Low-dose SRD significantly reduced hepatic TG and FBG (P<0.05). Metabolomic analysis showed that differential liver metabolites were enriched in tricarboxylic acid cycle (TAC) pathway in mice of high-dose SRD and HFD groups. Electron microscopy showed that high-dose SRD improved mitochondrial morphology and enhanced adenosine triphosphate production and fatty acid oxidation activity (both P<0.05). Additionally, high-dose SRD significantly decreased the contents of hydrogen peroxide and malondialdehyde in liver tissue and increased the content of superoxide dismutase (both P<0.05). Treatment with high-dose SRD resulted in a significant increase in both protein expression and activity of mitochondrial complex II. Additionally, high-dose SRD enhanced the protein expression of mitochondrial complex I (both P<0.05).
conclusionSRD exhibited hepatoprotective effects in MASLD, improving liver morphology, metabolism, and mitochondrial function, suggesting its potential as a therapeutic strategy for MASLD.
Indexed as
Identifiers
41139758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.